The Food and Drug Administration has issued a complete response letter to AstraZeneca regarding the supplemental New Drug Application (sNDA) for the use of dapagliflozin (Farxiga) as an adjunct treatment to insulin in patients with type 1 diabetes (T1D), when insulin alone does not provide adequate glycemic control. In a press statement, the Company noted…
Fresenius Kabi has announced the availability of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200mcg per 5mL and 500mcg per 5mL single-dose vials.
Medtronic is recalling the MiniMed 508 insulin pump and the MiniMed Paradigm series insulin pumps and providing alternative devices with enhanced cybersecurity features to affected patients.
Data from over 120,000 individuals was used to examine the association between intakes of n-6 polyunsaturated fatty acids (PUFAs) and type 2 diabetes risk.
Findings from a phase 3 study showed that dulaglutide (Trulicity; Lilly) at higher investigational doses demonstrated superiority in significantly reducing hemoglobin A1c in patients with type 2 diabetes (T2D).
The redesigned syringe includes a needle shield removal system and more stable plunger and thermoform tray with recessed areas designed to help prevent accidental plunger depression.
Researchers conducted a retrospective chart review on patients from an endocrinology clinic who initiated a GLP-1 agonist and/or SGLT-2 inhibitor after receiving U-500 insulin for at least 3 months.
FAERS database collects adverse events submitted by pharmaceutical companies, clinicians, and patients.
FDA has granted Breakthrough Therapy designation to avexitide (Eiger Biopharmaceuticals) for the treatment of post-bariatric hypoglycemia (PBH).
The approval of Victoza in this patient population was based on data from the ELLIPSE trial which included 134 children and adolescents.
